Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
18
ZEN.V Quote, Financials, Valuation and Earnings
Last price:
$1.00
Seasonality move
:
-1.07%
Day range:
$0.94 - $1.02
52-week range:
$0.85 - $2.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
114.11x
P/B ratio:
9.18x
Volume:
16.7K
Avg. volume:
40.7K
1-year change:
-18.03%
Market cap:
$107.3M
Revenue:
$872.5K
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ZEN.V
Zentek Ltd.
|
-- | -- | -- | -- | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LABS.TO
MediPharm Labs Corp.
|
$12.4M | -$0.01 | -1.82% | -- | -- |
|
MDNA.TO
Medicenna Therapeutics Corp.
|
-- | -- | -- | -- | $3.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ZEN.V
Zentek Ltd.
|
$1.00 | -- | $107.3M | -- | $0.00 | 0% | 114.11x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LABS.TO
MediPharm Labs Corp.
|
$0.08 | -- | $31.6M | -- | $0.00 | 0% | 0.68x |
|
MDNA.TO
Medicenna Therapeutics Corp.
|
$0.94 | $3.88 | $78.4M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ZEN.V
Zentek Ltd.
|
13.91% | -0.347 | 1.7% | 0.41x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LABS.TO
MediPharm Labs Corp.
|
1.11% | -1.209 | 1.34% | 1.97x |
|
MDNA.TO
Medicenna Therapeutics Corp.
|
1.43% | -0.349 | 0.18% | 3.53x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ZEN.V
Zentek Ltd.
|
-$1.2M | -$2.4M | -50.39% | -54.49% | -38887.1% | -$1.5M |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LABS.TO
MediPharm Labs Corp.
|
$2.4M | -$2.1M | -18.99% | -19.19% | -18.68% | -$127K |
|
MDNA.TO
Medicenna Therapeutics Corp.
|
-$23K | -$5.5M | -83.92% | -84.77% | -- | -$4.9M |
Zentek Ltd. vs. Competitors
-
Which has Higher Returns ZEN.V or COOL.CX?
Core One Labs, Inc. has a net margin of -38567.74% compared to Zentek Ltd.'s net margin of --. Zentek Ltd.'s return on equity of -54.49% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About ZEN.V or COOL.CX?
Zentek Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Zentek Ltd. has higher upside potential than Core One Labs, Inc., analysts believe Zentek Ltd. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ZEN.VZentek Ltd.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is ZEN.V or COOL.CX More Risky?
Zentek Ltd. has a beta of 0.498, which suggesting that the stock is 50.176% less volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock ZEN.V or COOL.CX?
Zentek Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentek Ltd. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZEN.V or COOL.CX?
Zentek Ltd. quarterly revenues are $6.2K, which are larger than Core One Labs, Inc. quarterly revenues of --. Zentek Ltd.'s net income of -$2.4M is higher than Core One Labs, Inc.'s net income of --. Notably, Zentek Ltd.'s price-to-earnings ratio is -- while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentek Ltd. is 114.11x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns ZEN.V or CURE.X.CX?
Biocure Technology has a net margin of -38567.74% compared to Zentek Ltd.'s net margin of --. Zentek Ltd.'s return on equity of -54.49% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About ZEN.V or CURE.X.CX?
Zentek Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Zentek Ltd. has higher upside potential than Biocure Technology, analysts believe Zentek Ltd. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings ZEN.VZentek Ltd.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is ZEN.V or CURE.X.CX More Risky?
Zentek Ltd. has a beta of 0.498, which suggesting that the stock is 50.176% less volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZEN.V or CURE.X.CX?
Zentek Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentek Ltd. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZEN.V or CURE.X.CX?
Zentek Ltd. quarterly revenues are $6.2K, which are larger than Biocure Technology quarterly revenues of --. Zentek Ltd.'s net income of -$2.4M is higher than Biocure Technology's net income of --. Notably, Zentek Ltd.'s price-to-earnings ratio is -- while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentek Ltd. is 114.11x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns ZEN.V or HEAL.CX?
has a net margin of -38567.74% compared to Zentek Ltd.'s net margin of --. Zentek Ltd.'s return on equity of -54.49% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M HEAL.CX-- -- -- -
What do Analysts Say About ZEN.V or HEAL.CX?
Zentek Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Zentek Ltd. has higher upside potential than , analysts believe Zentek Ltd. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings ZEN.VZentek Ltd.0 0 0 HEAL.CX0 0 0 -
Is ZEN.V or HEAL.CX More Risky?
Zentek Ltd. has a beta of 0.498, which suggesting that the stock is 50.176% less volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ZEN.V or HEAL.CX?
Zentek Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentek Ltd. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZEN.V or HEAL.CX?
Zentek Ltd. quarterly revenues are $6.2K, which are larger than quarterly revenues of --. Zentek Ltd.'s net income of -$2.4M is higher than 's net income of --. Notably, Zentek Ltd.'s price-to-earnings ratio is -- while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentek Ltd. is 114.11x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M HEAL.CX-- -- -- --
-
Which has Higher Returns ZEN.V or LABS.TO?
MediPharm Labs Corp. has a net margin of -38567.74% compared to Zentek Ltd.'s net margin of -18.71%. Zentek Ltd.'s return on equity of -54.49% beat MediPharm Labs Corp.'s return on equity of -19.19%.
Company Gross Margin Earnings Per Share Invested Capital ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M LABS.TOMediPharm Labs Corp.21.17% -$0.01 $38.3M -
What do Analysts Say About ZEN.V or LABS.TO?
Zentek Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand MediPharm Labs Corp. has an analysts' consensus of -- which suggests that it could grow by 33.33%. Given that MediPharm Labs Corp. has higher upside potential than Zentek Ltd., analysts believe MediPharm Labs Corp. is more attractive than Zentek Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZEN.VZentek Ltd.0 0 0 LABS.TOMediPharm Labs Corp.0 1 0 -
Is ZEN.V or LABS.TO More Risky?
Zentek Ltd. has a beta of 0.498, which suggesting that the stock is 50.176% less volatile than S&P 500. In comparison MediPharm Labs Corp. has a beta of 0.637, suggesting its less volatile than the S&P 500 by 36.251%.
-
Which is a Better Dividend Stock ZEN.V or LABS.TO?
Zentek Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediPharm Labs Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentek Ltd. pays -- of its earnings as a dividend. MediPharm Labs Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZEN.V or LABS.TO?
Zentek Ltd. quarterly revenues are $6.2K, which are smaller than MediPharm Labs Corp. quarterly revenues of $11.4M. Zentek Ltd.'s net income of -$2.4M is lower than MediPharm Labs Corp.'s net income of -$2.1M. Notably, Zentek Ltd.'s price-to-earnings ratio is -- while MediPharm Labs Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentek Ltd. is 114.11x versus 0.68x for MediPharm Labs Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M LABS.TOMediPharm Labs Corp.0.68x -- $11.4M -$2.1M
-
Which has Higher Returns ZEN.V or MDNA.TO?
Medicenna Therapeutics Corp. has a net margin of -38567.74% compared to Zentek Ltd.'s net margin of --. Zentek Ltd.'s return on equity of -54.49% beat Medicenna Therapeutics Corp.'s return on equity of -84.77%.
Company Gross Margin Earnings Per Share Invested Capital ZEN.VZentek Ltd.-19032.26% -$0.02 $13.6M MDNA.TOMedicenna Therapeutics Corp.-- -$0.06 $10.4M -
What do Analysts Say About ZEN.V or MDNA.TO?
Zentek Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Medicenna Therapeutics Corp. has an analysts' consensus of $3.88 which suggests that it could grow by 312.23%. Given that Medicenna Therapeutics Corp. has higher upside potential than Zentek Ltd., analysts believe Medicenna Therapeutics Corp. is more attractive than Zentek Ltd..
Company Buy Ratings Hold Ratings Sell Ratings ZEN.VZentek Ltd.0 0 0 MDNA.TOMedicenna Therapeutics Corp.4 0 0 -
Is ZEN.V or MDNA.TO More Risky?
Zentek Ltd. has a beta of 0.498, which suggesting that the stock is 50.176% less volatile than S&P 500. In comparison Medicenna Therapeutics Corp. has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.118%.
-
Which is a Better Dividend Stock ZEN.V or MDNA.TO?
Zentek Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medicenna Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zentek Ltd. pays -- of its earnings as a dividend. Medicenna Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ZEN.V or MDNA.TO?
Zentek Ltd. quarterly revenues are $6.2K, which are larger than Medicenna Therapeutics Corp. quarterly revenues of --. Zentek Ltd.'s net income of -$2.4M is higher than Medicenna Therapeutics Corp.'s net income of -$4.9M. Notably, Zentek Ltd.'s price-to-earnings ratio is -- while Medicenna Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zentek Ltd. is 114.11x versus -- for Medicenna Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ZEN.VZentek Ltd.114.11x -- $6.2K -$2.4M MDNA.TOMedicenna Therapeutics Corp.-- -- -- -$4.9M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
